2023
Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Zisook S, Mohamed S. Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report. Psychiatric Research And Clinical Practice 2023, 5: 131-143. PMID: 38077276, PMCID: PMC10698706, DOI: 10.1176/appi.prcp.20230017.Peer-Reviewed Original ResearchGroup-based trajectory modelingBaseline depressionEarly improvementSwitching treatmentSingle-blind trialHigher baseline depressionDepression symptom changeAdditional exploratory analysesAssociation of treatmentMajor depressive disorderLogistic regression analysisDepression Outcomes studyDemographic factorsMultinomial logistic regression analysisSpecific depression symptomsExploratory analysisProbability of responseAntidepressant trialsSeverity scoreDepressive disorderTrial reportsOutcome studiesBaseline anxietyPrimary analysisTreatment interventions
2019
Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Mohamed S, Zisook S. Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report. Psychiatric Research And Clinical Practice 2019, 1: 58-67. PMID: 36101874, PMCID: PMC9176018, DOI: 10.1176/appi.prcp.20190003.Peer-Reviewed Original ResearchNegative predictive valuePositive predictive valueEarly improvementWeek 2Antidepressant therapyAntidepressant treatmentPredictive valueSingle-blind trialDepressive Symptomatology-Clinician RatedMajor depressive disorderDepression Outcomes studyWeek 12Medication interventionsQuick InventoryDepressive disorderWeek 6Trial reportsOutcome studiesTreatment groupsDegree of improvementSwitching treatmentClinical decisionSecondary analysisRemissionMinimal improvementGeneral Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2001
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients
Kasckow J, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste D. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International Journal Of Geriatric Psychiatry 2001, 16: 1163-1167. PMID: 11748776, DOI: 10.1002/gps.508.Peer-Reviewed Original ResearchConceptsCitalopram augmentationScale scoreClinical Global Impression Scale scoresHamilton Depression Rating Scale scoresLarge double-blind studyDepression Rating Scale scoresAugmentation of antipsychoticsUsefulness of antidepressantsDouble-blind studySingle-blind trialMajor side effectsOlder schizophrenia patientsRating Scale scoresStable dosesElderly patientsOlder patientsAntipsychotic treatmentCitalopram groupDepressive symptomsSide effectsPatientsSchizophrenia patientsControl groupNegative symptomsAntipsychotics